Free Trial

Polianta Ltd Purchases Shares of 20,500 CVS Health Corporation $CVS

CVS Health logo with Medical background

Key Points

  • Polianta Ltd acquired 20,500 shares of CVS Health, valued at approximately $1.41 million, as part of their second-quarter investments.
  • CVS Health's stock currently has a consensus target price of $77.89, with a rating of "Moderate Buy" from analysts, who have varied opinions ranging from "hold" to "strong-buy."
  • The company declared a quarterly dividend of $0.665 per share, representing an annualized dividend yield of 3.6% and highlighting a payout ratio of 74.30%.
  • Five stocks to consider instead of CVS Health.

Polianta Ltd acquired a new position in shares of CVS Health Corporation (NYSE:CVS - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 20,500 shares of the pharmacy operator's stock, valued at approximately $1,414,000. CVS Health makes up about 0.6% of Polianta Ltd's investment portfolio, making the stock its 27th biggest position.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of CVS Health by 0.8% during the first quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator's stock valued at $8,017,223,000 after purchasing an additional 969,027 shares during the last quarter. Dodge & Cox lifted its position in CVS Health by 4.8% in the first quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator's stock worth $4,976,856,000 after purchasing an additional 3,353,223 shares during the period. Invesco Ltd. lifted its position in shares of CVS Health by 13.2% during the 1st quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator's stock valued at $1,383,039,000 after acquiring an additional 2,375,764 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of CVS Health by 14.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,309,289 shares of the pharmacy operator's stock valued at $1,037,205,000 after acquiring an additional 1,942,886 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in CVS Health by 5.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 13,647,873 shares of the pharmacy operator's stock valued at $924,643,000 after purchasing an additional 728,924 shares during the period. Institutional investors and hedge funds own 80.66% of the company's stock.

Insider Transactions at CVS Health

In other news, Director Anne A. Finucane sold 7,500 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the sale, the director owned 22,156 shares of the company's stock, valued at approximately $1,573,519.12. This represents a 25.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.22% of the stock is owned by corporate insiders.

CVS Health Stock Performance

CVS traded up $0.04 on Monday, reaching $74.96. The company had a trading volume of 2,507,159 shares, compared to its average volume of 9,535,027. CVS Health Corporation has a fifty-two week low of $43.56 and a fifty-two week high of $76.24. The stock has a market cap of $95.08 billion, a P/E ratio of 20.93, a P/E/G ratio of 0.83 and a beta of 0.62. The company's fifty day moving average is $67.91 and its 200 day moving average is $66.64. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The business had revenue of $98.92 billion for the quarter, compared to analyst estimates of $94.87 billion. During the same quarter in the prior year, the business earned $1.83 EPS. CVS Health's quarterly revenue was up 8.4% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be issued a $0.665 dividend. The ex-dividend date of this dividend is Thursday, October 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 3.5%. CVS Health's payout ratio is currently 74.30%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on CVS shares. Zacks Research downgraded shares of CVS Health from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 8th. Jefferies Financial Group upped their price target on shares of CVS Health from $74.00 to $80.00 and gave the stock a "buy" rating in a research note on Monday, June 30th. Wall Street Zen raised shares of CVS Health from a "hold" rating to a "buy" rating in a research note on Sunday. Bernstein Bank dropped their price target on shares of CVS Health from $78.00 to $72.00 and set a "market perform" rating on the stock in a research note on Wednesday, July 16th. Finally, UBS Group raised shares of CVS Health from a "neutral" rating to a "buy" rating and upped their price target for the stock from $67.00 to $79.00 in a research note on Monday, August 18th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, CVS Health presently has a consensus rating of "Moderate Buy" and an average target price of $78.25.

Get Our Latest Report on CVS Health

CVS Health Company Profile

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

See Also

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Should You Invest $1,000 in CVS Health Right Now?

Before you consider CVS Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.

While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.